DUBLIN and LONDON, April 17 /PRNewswire-FirstCall/ -- Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"), (AIM:AP.L), the Healthcare Innovation Group focused on the Wound Care, Oral Care and Cardiovascular Health markets was informed today that Tony Richardson, Chief Executive Officer of the Company, acquired 150,000 ordinary shares of EUR0.0125 each ("Ordinary Shares") on 17 April 2007. The Ordinary Shares were bought at GBP0.12 p each and following this acquisition, Mr Richardson now holds a total of 1,885,306 Ordinary Shares, which represents approximately 1.36 per cent of the Company's issued share capital.
For Further Information Contact: Dublin: Denise Cronin Alltracel: +353-1-235-2162 press@alltracel.com London: Deborah Scott Financial Dynamics: +44-(0)207-831-3113 New York: Sean Leous Financial Dynamics: +1-212-850-5626
Notes to Editors
Alltracel, (AIM: AP.L) (www.alltracel.com) the Healthcare Innovation group is focused on taking proprietary technology from research right through to commercialisation in the global healthcare market.
Alltracel Pharmaceuticals Plc., ("Alltracel") was founded in 1996 and is a public company which listed on London's Alternative Investment Market in July 2001.
With corporate headquarters in Dublin, Ireland; Alltracel has a commercial office in London, England; R&D subsidiary in the Czech Republic and manufacturing facilities in Shenzhen, China. Alltracel also has a wide network of research, development and manufacturing partners in Europe, Asia and North America.
Alltracel operates via two main divisions Alltracel Healthcare Group and Alltracel Healthcare Technologies:
Alltracel Healthcare Technologies is focused on the commercialisation effort behind proven innovation technologies and services for the global healthcare market. Alltracel Healthcare Group has a range of stake holdings, joint ventures and wholly owned business units operating in a variety of healthcare categories including Wound Care, Oral Care, Cardiovascular Health.
- Alltracel's specialist Oral Care subsidiary Westone (www.westone.com) is headquartered in London, England and is the leading contract supply and manufacturing partner for the European private label inter-dental market. Westone also partners with a number of leading oral care brands internationally.
- Alltracel's specialist Nanotechnology subsidiary Nanopeutics(TM) (www.nanopeutics.net) is headquartered in Liberec in the Czech Republic and is dedicated to the commercialisation of Nanospider(TM) technology for the global healthcare market.
Alltracel Healthcare Technologies specialises in innovation, research, development and the deployment of proprietary technology in the global healthcare market. Alltracel Healthcare Technologies has established a substantial intellectual property portfolio with patents in a number of healthcare applications areas.
m-doc(TM) is a trademark of Alltracel Pharmaceuticals PLC.
Nanospider(TM) and Nanopeutics(TM) are trademarks controlled by Nanopeutics s.r.o.
Alltracel Pharmaceuticals Plc.CONTACT: For Further Information Contact: Dublin: Denise Cronin,Alltracel: +353-1-235-2162, press@alltracel.com. London: Deborah Scott,Financial Dynamics: +44-(0)207-831-3113, New York: Sean Leous, FinancialDynamics: +1-212-850-5626
